VEGFA and neoplasm: These effects of belzutifan did not appear to be a secondary consequence of tumor shrinkage and loss of viable tumor cells because (1) they occurred rapidly, (2) were observed in both belzutifan responders and nonresponders, and (3) the clinical response rate to belzutifan, if anything, trended lower than the response rates to ICI and VEGF TKI in our cohorts (Extended Data Fig. 8f and Extended Data Table 1).